B
Bull
Bull · 25%MRUS
$71.17
情境價格
$90.000
-6.426 (-7.14%)收盤時
Loading chart…
- High
- 96.860
- Open
- 96.860
- VWAP
- 91.33
- Vol
- 2.73M
- Mkt Cap
- 4.06B
- Low
- 87.140
- Amount
- 249.22M
- EV/EBITDA, TTM
- -8.67
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.
Analyst Ratings (5)
+8.57% upside
Buy
4 Buy
1 Hold
0 Sell
Current: 90.00
最低
92.00
平均
97.71
最高
112.00
Barclays
Equal Weight
$97
2025-09-30
Barclays
2025-09-30
目標價
$97
Equal Weight
BMO Capital
Market Perform
$97
2025-09-30
BMO Capital
2025-09-30
目標價
$97
Market Perform
UBS
Neutral
$97
2025-09-30
UBS
2025-09-30
目標價
$97
Neutral
LifeSci Capital
Market Perform
$97
2025-09-29
LifeSci Capital
2025-09-29
目標價
$97
Market Perform
Needham
Hold
—
2025-09-29
Needham
2025-09-29
目標價
—
Hold
估值指標
The current forward P/E ratio for Merus NV (MRUS) is -11.82, compared to its 5-year average forward P/E of -11.03.
Alphio AI Price Scenarios for MRUS
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
事件時間軸
資訊
5.005-07NewsfilterLeonaBio Appoints New Board Members to Drive Growth
- 8.502-11Newsfilter
Growth Prospects for the EGFR-NSCLC Market Analyzed
- 9.012-16Newsfilter
Oncolytics Biotech Achieves 33% Response Rate in KRAS-Mutant Colorectal Cancer
9.012-16PRnewswireOncolytics Biotech Achieves 33% Response Rate in KRAS-Mutant Colorectal Cancer
8.512-12GlobenewswireGenmab Acquires Merus, Anticipates $1 Billion EBITDA by 2029
MRUS FAQ — answered by Alphio AI
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
5 analysts cover MRUS: 4 rate it Buy, 1 Hold and 0 Sell. The average price target is 97.71.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。